Securian Asset Management Inc. Has $496,000 Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Securian Asset Management Inc. lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,686 shares of the medical research company’s stock after selling 100 shares during the quarter. Securian Asset Management Inc.’s holdings in Charles River Laboratories International were worth $496,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc lifted its holdings in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the period. Pinnacle Bancorp Inc. raised its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the period. Tortoise Investment Management LLC boosted its holdings in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $56,000. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research note on Monday, March 3rd. Robert W. Baird decreased their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Bank of America dropped their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Finally, William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $175.02 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $167.46 and a two-hundred day simple moving average of $184.33. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $274.77. The firm has a market capitalization of $8.95 billion, a PE ratio of 1,166.77, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.46 earnings per share. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).